摘要
目的:探究分析持续导管引流联合顺铂或博莱霉素心包灌注治疗肺癌性心包积液的临床疗效观察。方法:抽选在濮阳市人民医院进行治疗的60例肺癌性心包积液患者,并按照随机分配制度将其平均分为两组治疗组(观察组与对照组)进行不同药物治疗,每组患者各30例。全部患者均使用持续导管引流进行治疗,而观察组此治疗基础上加以顺铂,而对照组加以博莱霉素心包。对比分析两组患者的临床效果、不良反应以及肿瘤标志物水平。结果:观察组的总有效率和不良反应发生率分别为96.67%和10%,对照组的总有效率和不良反应发生率分别为76.67%和30%,相比观察组,对照组的总有效率不仅比较低,不良反应发生率也比较低,数据存在差异具有统计学意义(P<0.05);观察组细胞角蛋白19片段(CYFRA21-1)、癌胚抗原(CEA)、神经特异性烯醇化酶(NSE)等指标优于对照组,数据存在差异具有统计学意义(P<0.05)。结论:博莱霉素在持续导管引流的治疗基础上运用于肺癌性心包积液具有显著的临床疗效,能够有效提高患者的临床效果,降低患者的不良反应发生率,改善的肿瘤标志物水平,是值得在临床上推广应用的良好治疗手段。
Objective:To investigate the clinical efficacy of continuous catheter drainage combined with cisplatin,or bolemycinpericardium perfusion therapy for lung cancer.Methods:60cases of lung cancer patients with pericardial effusion in our hospital wererandomly divided into two groups,the treatment group(observation group)and control group,30cases in each group of patients.All patients were treated with continuous catheter drainage,while the group was based on the treatment based on cisplatin,while thecontrol group was given a pericycin pericardium.The clinical effects,adverse reactions and the level of tumor markers were analyzed.Results:Total effective rate and incidence of adverse reactions were96.67%and10%respectively in the observation group and thecontrol group;total effective rate and the incidence of adverse reactions were76.67%and30%respectively in the observation groupand the control group.Compared with the control group,total effective rate was high,and with low incidence of adverse reactions in theobservation group(P<0.05);cytokeratin19fragment(CYFRA21-1),carcinoembryonic antigen(CEA),neural specificity enolizationenzyme(NSE),and other indicators is better in the observation group compared with that of control group,data differences statisticallysignificant(P<0.05).Conclusion:Lai toxin in the treatment of continuous catheter drainage in lung cancer on the basis of pericardialeffusion has significant clinical curative effect,can effectively improve the clinical effect of patients,reduce the incidence of adversereactions of patients and improve the level of tumor markers,it is worth in the clinical application of good treatment.
作者
于海明
王江波
YU Hai-ming;WANG Jiang-bo(Department of Cardiothoracic Surgery, Puyang City People 's Hospital, Puyang Henan 457000, China)
出处
《药品评价》
CAS
2017年第17期39-41,64,共4页
Drug Evaluation
关键词
持续导管引流
顺铂
博莱霉素
肺癌性心包积液
安全性
临床效果
Continuous Catheter Drainage
Cisplatin Lai Toxin
Lung Cancer Sexual Pericardial Effusion
Security
Clinical Effect
